Buy Ajanta Pharma; target of Rs 3200: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3200 in its research report dated December 24, 2025.

Broker Research

December 26, 2025 / 12:01 IST

Buy

Prabhudas Lilladher's research report on Ajanta Pharma

Ajanta Pharma (AJP IN) signs an in-licensing agreement with Biocon for marketing semaglutide in 26 countries across RoW markets. Given that AJP will be involved in the registration process to get approvals across these markets, we expect it to generate healthy margins. Further, AJP’s strong franchise and field force across these markets will enable it to garner higher market share. We expect semaglutide to provide additional ~Rs2bn of sales for AJP with healthy margins in FY28E. Strong annual free cash flow of Rs8–10bn further supports sustained investments and potential inorganic opportunities, reinforcing medium-term growth visibility. Overall, we expect EBITDA/PAT CAGR of 17%/ 14% over FY25-28E with healthy RoE/RoCE of 28.1%/35.5% in FY27E.

Outlook

At CMP, AJP is trading at 24x P/E and 17.1x EV/EBITDA as of Sep’27E. We value AJP at 30x P/E as of Sep’27E EPS based on its ability to generate higher RoE/RoCE compared to peers and strong exposure to BGx markets. Maintain ‘BUY’ rating with TP of Rs3,200/share.

For all recommendations report, click here